New York, January 18, 2026, 10:06 EST — Market closed
- On Friday, Eli Lilly shares ended the day at $1,038.40, marking a 0.5% rise.
- Attention is now on when fast FDA reviews will land and how solid they’ll be legally, alongside what early prescription numbers reveal about the coming obesity-drug competition.
- The U.S. markets will be closed Monday. Trading resumes Tuesday, with Lilly’s earnings call for Feb. 4 coming up next.
Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open.
Why it matters now: Lilly’s next valuation boost hinges on weight loss, and investors are weighing two fresh signals — the speed of the U.S. drug regulator’s action, and whether pills can expand demand beyond injections.
The setup is more delicate than it appears. Speeding up the timeline for a new oral obesity drug could shift revenue expectations, but any slip in trust around fast approvals might trigger lawsuits and stricter label reviews down the line.
A Reuters report on Friday highlighted growing unease among some drugmakers over legal risks tied to the FDA Commissioner’s National Priority Voucher Program, designed to fast-track decisions on select drugs within one to two months. Eli Lilly’s much-anticipated weight-loss pill falls under this program. Lilly’s research chief, Dan Skovronsky, commented, “We’ve just started, so let’s see how it goes.” Reuters
Competition is heating up. Novo Nordisk’s Wegovy weight-loss pill racked up 3,071 retail prescriptions in just four days after its January debut, according to IQVIA data highlighted by analysts in a separate Reuters report. This early figure is being eyed closely as it signals a shift toward cash-pay patients—those footing the bill themselves. Ro CEO Zach Reitano noted “early signs” of growing interest in the pill on their platform.
Outside the U.S., regulators are widening their approach. Britain’s MHRA greenlit a higher max weekly dose of Novo’s Wegovy — 7.2 mg split into three injections — after trial data showed roughly 20% weight loss, Reuters reported. The move keeps pressure on rivals to boost effectiveness without altering the molecule.
There’s a snag for bulls: faster reviews don’t automatically mean quicker launches. Legal and safety checks tied to tighter schedules can backfire. On the commercial front, pill adoption depends on pricing, supply, and insurance moves. Early prescription data can be deceptive when online pharmacies and telehealth channels fluctuate week to week.
The calendar plays a role as well. U.S. markets will shut down Monday in observance of Martin Luther King Jr. Day, pushing the next opportunity for investors to adjust positions to Tuesday.
Lilly’s next big event is its fourth-quarter 2025 earnings call set for Feb. 4. Investors will watch closely for updates on manufacturing, demand trends for its obesity and diabetes treatments, and any new insights on the development of an oral obesity pill.
Once Tuesday’s market reopens, traders will zero in on fresh prescription data in the obesity-drug pill sector. They’ll also be on alert for any updates from the FDA regarding the practical use of the voucher program, especially to see if the agency’s expedited review process can withstand scrutiny.
